

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



康臣葯業集團有限公司
CONSUN PHARMACEUTICAL GROUP LIMITED

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1681)

VOLUNTARY ANNOUNCEMENT

INCREASE IN SHAREHOLDING BY SUBSTANTIAL SHAREHOLDER

Consun Pharmaceutical Group Limited (the “**Company**”) was informed by Ms. LI Qian, an executive director, the chief executive officer and a substantial shareholder of the Company, that during the period from 27 May 2016 to 6 July 2016, Ms. LI Qian (through herself and/or her holding companies) acquired a total of 2,569,000 shares of the Company in the open market, for a total consideration of approximately HK\$10,107,000, respectively (the “**Acquisition**”).

Immediately after the Acquisition, Ms. LI Qian through herself and her holding companies were interested in a total of 140,566,261 shares of the Company, respectively, representing approximately 14.42% of the total issued share capital of the Company.

By order of the Board
Consun Pharmaceutical Group Limited
AN Yubao
Chairman

Hong Kong, 11 July 2016

As at the date of this announcement, the Board comprises Mr. AN Yubao, Ms. LI Qian and Professor ZHU Quan as executive Directors; Mr. WANG Shunlong and Mr. LIN Sheng as non-executive Directors; Mr. SU Yuanfu, Mr. FENG Zhongshi and Ms. CHENG Xinxin as independent non-executive Directors.